Key result
IV thrombolysis linked to better 3-month functional status without increased mortality in nonagenarians.
Why the study?
Only inconclusive data were available regarding intravenous thrombolysis for acute ischemic stroke in patients older than 90 years.
Observational (n=52)
Hypothesis-generating for thrombolysis in nonagenarians; prospective randomized trials needed before practice change.
Concerning intravenous thrombolysis, only inconclusive data are available for patients older than 90. We retrospectively evaluated 11 such patients whom we treated with thrombolysis from June 2007 through April 2012, comparing them to 41 patients of the same age whom we treated conventionally in the same period. Baseline clinical data were superimposable, except for shorter onset-to-hospital time for thrombolyzed patients. Mortality and hemorrhagic transformation did not differ. Functional status (modified Rankin scale) 3 months after was better in treated patients, even when compared to controls who arrived early in the hospital. Treated patients were more often discharged home or to intensive rehabilitation, less often to a nursing home. We conclude that safety and effectiveness of intravenous thrombolysis in eligible nonagenarians are evident in a setting of everyday practice, and that patients 90 years or older should not be denied thrombolysis solely on the basis of their age.
No takes yet. Share an insight, caveat, or question.
Balestrino et al. (2013) conducted an observational in Acute ischemic stroke (n=52). Intravenous thrombolysis vs. Conventional treatment was evaluated on Functional status (modified Rankin scale) at 3 months, mortality, and hemorrhagic transformation. Intravenous thrombolysis in patients ≥90 years old (n=11 vs 41 controls) resulted in better 3-month modified Rankin scale functional status with no difference in mortality or hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: